Document is current
Any future updates will be listed below
-
Authors
Das, Suradip https://orcid.org/0000-0002-5716-6605
Gordián-Vélez, Wisberty J.
Ledebur, Harry C.
Mourkioti, Foteini https://orcid.org/0000-0002-7119-6640
Rompolas, Panteleimon
Chen, H. Isaac
Serruya, Mijail D.
Cullen, D. Kacy https://orcid.org/0000-0002-5355-5216
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Defense
National Science Foundation (NSF) Graduate Research Fellowship
- License Information
-
More Information
Article History
Received: 19 December 2019
Accepted: 29 April 2020
First Online: 5 June 2020
Competing interests
: D.K.C and H.C.L. are co-founders of Axonova Medical, LLC, and D.K.C. is a co-founder of INNERVACE, Inc., which are University of Pennsylvania spin-out companies focused on translation of advanced regenerative therapies to treat nervous system disorders. Multiple patents relate to the composition, methods, and use of the constructs described in the paper, including U.S. Patent 9,895,399 (D.K.C.), U.S. Patent App. 15/032,677 (D.K.C.), U.S Provisional Patent App. 62/322,434 (D.K.C., H.I.C., M.D.S.), U.S. Provisional Patent 62/569,255 (D.K.C), and U.S. Provisional Patent App. 62/758,203 (D.K.C, S.D., W.G.V.). No other author declares competing interests.
